MCID: OVR011
MIFTS: 26

Ovarian Mucinous Adenocarcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Adenocarcinoma

Aliases & Descriptions for Ovarian Mucinous Adenocarcinoma:

Name: Ovarian Mucinous Adenocarcinoma 12 14 69
Mucinous Carcinoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3606
NCIt 47 C5243
UMLS 69 C1335167

Summaries for Ovarian Mucinous Adenocarcinoma

MalaCards based summary : Ovarian Mucinous Adenocarcinoma, also known as mucinous carcinoma of ovary, is related to mucinous adenocarcinoma of ovary and adenocarcinoma. An important gene associated with Ovarian Mucinous Adenocarcinoma is CDX2 (Caudal Type Homeobox 2). The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, and related phenotype is Decreased Hepatitis C virus replication.

Related Diseases for Ovarian Mucinous Adenocarcinoma

Diseases related to Ovarian Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 mucinous adenocarcinoma of ovary 11.1
2 adenocarcinoma 10.2
3 mucinous adenocarcinoma 10.2
4 peripheral nervous system ganglioneuroblastoma 10.2 AMACR CDX2
5 peritoneal benign neoplasm 10.2 CDX2 KRT20
6 dystonia 10.2 CDX2 KRT20
7 anal canal paget's disease 10.2 CDX2 KRT20
8 extramedullary plasmacytoma 10.2 CDX2 KRT20
9 apocrine adenocarcinoma 10.2 CDX2 KRT20
10 mucosal melanoma 10.2 CDX2 KRT20
11 spastic ataxia 5 10.2 CDX2 KRT20
12 large cell neuroendocrine carcinoma 10.2 CDX2 KRT20
13 giant cell tumor 10.2 CDX2 KRT20
14 colon signet ring adenocarcinoma 10.1 AMACR KRT20
15 mesenchymoma 10.1 CDX2 KRT20
16 renal pelvis carcinoma 10.1 AMACR UPK3A
17 hunter macpherson syndrome 10.1 CDX2 KRT20
18 choroid epithelioid cell melanoma 10.1 CDX2 MUC2
19 thymus gland disease 10.1 AMACR UPK3A
20 churg-strauss syndrome 10.1 CDX2 KRT20
21 ureter adenocarcinoma 10.1 CDX2 MUC2
22 perivascular epithelioid cell tumor 10.1 KRT20 UPK3A
23 iris spindle cell melanoma 10.1 AMACR UPK3A
24 exposure keratitis 10.1 CDX2 MUC2
25 fuchs' heterochromic uveitis 10.1 AMACR UPK3A
26 meninges hemangiopericytoma 10.1 CDX2 KRT20
27 vulva squamous cell carcinoma 10.1 KRT20 UPK3A
28 klatskin's tumor 10.1 KRT20 UPK3A
29 angiolipomatosis, familial 10.1 KRT20 UPK3A
30 uterine corpus endometrial stromal sarcoma 10.1 KRT20 UPK3A
31 embryonal testis carcinoma 10.1 KRT20 UPK3A
32 acute eustachian salpingitis 10.1 CDX2 MUC2
33 aicardi-goutieres syndrome 10.1 CDX2 MUC2
34 ascending colon cancer 10.1 KRT20 MUC2
35 lateral sinus thrombosis 10.1 CDX2 MUC2
36 trophoblastic neoplasm 10.1 KRT20 MUC2
37 ariboflavinosis 10.1 CDX2 KRT20
38 sclerosing hemangioma 10.1 CDX2 MUC2
39 vaginal villous adenoma 10.1 CDX2 MUC2
40 sarcomatoid mesothelioma 10.1 AMACR MUC2
41 appendix mucinous cystadenocarcinoma 10.1 KRT20 MUC2
42 spastic diplegia infantile type 10.1 CDX2 MUC2
43 rhinitis 10.1 AMACR KRT20
44 his bundle tachycardia 10.1 CDX2 MUC2
45 fallopian tube adenocarcinoma 10.1 CDX2 KRT20
46 lung clear cell carcinoma 10.0 KRT20 MUC2
47 small intestine carcinoid neuroendocrine tumor 10.0 KRT20 MUC2
48 pericholangitis 10.0 CDX2 MUC2
49 placental site trophoblastic tumor 10.0 KRT20 MUC2
50 struma ovarii 10.0 KRT20 MUC2

Graphical network of the top 20 diseases related to Ovarian Mucinous Adenocarcinoma:



Diseases related to Ovarian Mucinous Adenocarcinoma

Symptoms & Phenotypes for Ovarian Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Hepatitis C virus replication GR00180-A-1 8.92 NOM1 UPK3A
2 Decreased Hepatitis C virus replication GR00180-A-2 8.92 NOM1 UPK3A

Drugs & Therapeutics for Ovarian Mucinous Adenocarcinoma

Drugs for Ovarian Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
7
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
8
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
9
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
10
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
11
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
12
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
13
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
14
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
15
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
16
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
17
Epirubicin Approved Phase 3 56420-45-2 41867
18
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
19
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
20
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
23
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
24
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
25
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
26
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
27 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
28 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
29 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
36 Alkylating Agents Phase 3,Phase 2,Phase 1
37 topoisomerase I inhibitors Phase 2, Phase 3, Phase 1
38 Mitogens Phase 3,Phase 2,Phase 1
39 Selective Estrogen Receptor Modulators Phase 2, Phase 3
40 Hormone Antagonists Phase 2, Phase 3
41 Hormones Phase 2, Phase 3
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
43 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
44 Estrogen Receptor Modulators Phase 2, Phase 3
45 Estrogens Phase 2, Phase 3
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
47 Immunoglobulin G Phase 3,Phase 2,Phase 1
48 Immunoglobulins Phase 3,Phase 2,Phase 1
49 Anti-Infective Agents Phase 3,Phase 2,Phase 1
50 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 116)
id Name Status NCT ID Phase
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
2 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
7 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
8 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3
9 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
10 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
11 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
12 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
13 Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients Recruiting NCT01226394 Phase 3
14 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Recruiting NCT02125344 Phase 3
15 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
16 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
17 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
18 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3
19 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3
20 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02839707 Phase 2, Phase 3
21 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
22 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3
23 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
24 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
25 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2
26 Toremifene in Treating Patients With Ovarian Cancer Completed NCT00003865 Phase 2
27 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
28 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
29 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
30 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
31 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2
32 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2
33 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2
34 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2
35 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
36 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2
37 Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00993655 Phase 2
38 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2
39 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
40 Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients Completed NCT02575859 Phase 1, Phase 2
41 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2
42 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
43 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
44 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
45 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2
46 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2
47 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02345265 Phase 2
48 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2
49 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2
50 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Recruiting NCT02728258 Phase 2

Search NIH Clinical Center for Ovarian Mucinous Adenocarcinoma

Genetic Tests for Ovarian Mucinous Adenocarcinoma

Anatomical Context for Ovarian Mucinous Adenocarcinoma

MalaCards organs/tissues related to Ovarian Mucinous Adenocarcinoma:

39
Ovary

Publications for Ovarian Mucinous Adenocarcinoma

Articles related to Ovarian Mucinous Adenocarcinoma:

id Title Authors Year
1
Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma. ( 27060927 )
2016
2
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions. ( 26576867 )
2015
3
Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis. ( 25197383 )
2014
4
Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. ( 24487473 )
2014
5
A case of ovarian mucinous adenocarcinoma in a premenarcheal girl. ( 22016113 )
2012
6
Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma. ( 21556953 )
2011
7
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. ( 19926591 )
2010
8
Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. ( 15721446 )
2005
9
An ovarian mucinous adenocarcinoma arising from mature cystic teratoma associated with respiratory type tissue: a case report. ( 15656343 )
2004
10
Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. ( 9158713 )
1997

Variations for Ovarian Mucinous Adenocarcinoma

Cosmic variations for Ovarian Mucinous Adenocarcinoma:

9 (show top 50) (show all 97)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 4
2 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 4
3 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 4
4 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 4
5 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 4
6 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 4
7 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 4
8 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 4
9 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 4
10 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 4
11 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 4
12 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 4
13 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 4
14 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 4
15 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 4
16 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 4
17 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 4
18 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 4
19 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 4
20 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 4
21 COSM20640 WEE2 ovary,NS,carcinoma,mucinous carcinoma c.1193G>A p.R398H 3
22 COSM20669 ULK1 ovary,NS,carcinoma,mucinous carcinoma c.868G>A p.V290M 3
23 COSM20712 TRRAP ovary,NS,carcinoma,mucinous carcinoma c.5786G>T p.R1929L 3
24 COSM11205 TP53 ovary,NS,carcinoma,mucinous carcinoma c.796G>C p.G266R 3
25 COSM10891 TP53 ovary,NS,carcinoma,mucinous carcinoma c.814G>A p.V272M 3
26 COSM46470 TP53 ovary,NS,carcinoma,mucinous carcinoma c.922C>G p.L308V 3
27 COSM10656 TP53 ovary,NS,carcinoma,mucinous carcinoma c.742C>T p.R248W 3
28 COSM10725 TP53 ovary,NS,carcinoma,mucinous carcinoma c.701A>G p.Y234C 3
29 COSM10645 TP53 ovary,NS,carcinoma,mucinous carcinoma c.527G>T p.C176F 3
30 COSM43899 TP53 ovary,NS,carcinoma,mucinous carcinoma c.434T>C p.L145P 3
31 COSM6932 TP53 ovary,NS,carcinoma,mucinous carcinoma c.733G>A p.G245S 3
32 COSM10659 TP53 ovary,NS,carcinoma,mucinous carcinoma c.817C>T p.R273C 3
33 COSM10704 TP53 ovary,NS,carcinoma,mucinous carcinoma c.844C>T p.R282W 3
34 COSM44827 TP53 ovary,NS,carcinoma,mucinous carcinoma c.358A>G p.K120E 3
35 COSM11307 TP53 ovary,NS,carcinoma,mucinous carcinoma c.643A>T p.S215C 3
36 COSM10662 TP53 ovary,NS,carcinoma,mucinous carcinoma c.743G>A p.R248Q 3
37 COSM10648 TP53 ovary,NS,carcinoma,mucinous carcinoma c.524G>A p.R175H 3
38 COSM20645 TNK2 ovary,NS,carcinoma,mucinous carcinoma c.296G>A p.R99Q 3
39 COSM20667 TEX14 ovary,NS,carcinoma,mucinous carcinoma c.3363G>T p.K1121N 3
40 COSM20630 SRPK2 ovary,NS,carcinoma,mucinous carcinoma c.1438C>T p.Q480* 3
41 COSM20704 SPEG ovary,NS,carcinoma,mucinous carcinoma c.5707C>T p.R1903W 3
42 COSM20628 SNRK ovary,NS,carcinoma,mucinous carcinoma c.1831G>A p.G611S 3
43 COSM20718 SGK494 ovary,NS,carcinoma,mucinous carcinoma c.871C>T p.R291C 3
44 COSM20743 RPS6KC1 ovary,NS,carcinoma,mucinous carcinoma c.1988G>C p.G663A 3
45 COSM20685 RPS6KA2 ovary,NS,carcinoma,mucinous carcinoma c.1581+1G>A p.? 3
46 COSM20695 ROR1 ovary,NS,carcinoma,mucinous carcinoma c.448T>C p.F150L 3
47 COSM1716832 RNF43 ovary,NS,carcinoma,mucinous carcinoma c.850G>T p.E284* 3
48 COSM1172444 RNF43 ovary,NS,carcinoma,mucinous carcinoma c.142A>G p.I48V 3
49 COSM981860 RNF43 ovary,NS,carcinoma,mucinous carcinoma c.1009C>T p.R337* 3
50 COSM1716830 RNF43 ovary,NS,carcinoma,mucinous carcinoma c.16C>T p.Q6* 3

Expression for Ovarian Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Ovarian Mucinous Adenocarcinoma.

Pathways for Ovarian Mucinous Adenocarcinoma

GO Terms for Ovarian Mucinous Adenocarcinoma

Sources for Ovarian Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....